JP2004537576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537576A5 JP2004537576A5 JP2003518456A JP2003518456A JP2004537576A5 JP 2004537576 A5 JP2004537576 A5 JP 2004537576A5 JP 2003518456 A JP2003518456 A JP 2003518456A JP 2003518456 A JP2003518456 A JP 2003518456A JP 2004537576 A5 JP2004537576 A5 JP 2004537576A5
- Authority
- JP
- Japan
- Prior art keywords
- catechin
- amyloidosis
- disease
- pharmaceutical composition
- gallate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims 21
- 235000005487 catechin Nutrition 0.000 claims 21
- 206010002022 amyloidosis Diseases 0.000 claims 18
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 17
- 229950001002 cianidanol Drugs 0.000 claims 17
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 8
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims 6
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims 5
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims 5
- 102000003802 alpha-Synuclein Human genes 0.000 claims 5
- 108090000185 alpha-Synuclein Proteins 0.000 claims 5
- 235000012734 epicatechin Nutrition 0.000 claims 5
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims 5
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 claims 5
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 claims 4
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims 4
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims 4
- 150000001765 catechin Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 3
- 241000196324 Embryophyta Species 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 3
- 208000023769 AA amyloidosis Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 208000035474 group of disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000023761 AL amyloidosis Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 241000209507 Camellia Species 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 235000018597 common camellia Nutrition 0.000 claims 1
- 210000004262 dental pulp cavity Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000008864 scrapie Diseases 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27686601P | 2001-03-15 | 2001-03-15 | |
| US33896901P | 2001-12-10 | 2001-12-10 | |
| PCT/US2002/007755 WO2003013442A2 (en) | 2001-03-15 | 2002-03-15 | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004537576A JP2004537576A (ja) | 2004-12-16 |
| JP2004537576A5 true JP2004537576A5 (enExample) | 2005-12-22 |
Family
ID=26958170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518456A Pending JP2004537576A (ja) | 2001-03-15 | 2002-03-15 | アルツハイマー病、パーキンソン病、全身性ａａアミロイド症、および他のアミロイド疾患における線維新生の治療のためのカテキン類 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1372682B1 (enExample) |
| JP (1) | JP2004537576A (enExample) |
| AT (1) | ATE555807T1 (enExample) |
| CA (1) | CA2440293C (enExample) |
| DK (1) | DK1372682T3 (enExample) |
| ES (1) | ES2387910T3 (enExample) |
| NZ (1) | NZ528321A (enExample) |
| PT (1) | PT1372682E (enExample) |
| WO (1) | WO2003013442A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514107B2 (en) | 2002-03-21 | 2009-04-07 | Mars, Incorporated | Treatment of diseases involving defective gap junctional communication |
| US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| WO2004060791A1 (en) | 2003-01-07 | 2004-07-22 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
| EP1663199B1 (en) * | 2003-09-25 | 2013-04-03 | Tel Aviv University Future Technology Development L.P. | Compositions and methods using same for treating amyloid-associated diseases |
| WO2005031362A2 (en) | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
| EP1713457A2 (de) * | 2004-02-11 | 2006-10-25 | Max-Delbrück-Centrum Für Molekulare Medizin | Neue arzneimittel und diagnostische zusammensetzungen f r be handlung und diagnose von neurodegenerativen erkrankungen und amyloid-krankheiten |
| WO2006013552A2 (en) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
| US20100040558A1 (en) * | 2005-04-26 | 2010-02-18 | University Of South Florida | Green tea polyphenol alpha secretase enhancers and methods of use |
| JP2007022946A (ja) * | 2005-07-14 | 2007-02-01 | Mitsui Norin Co Ltd | マクロファージ遊走阻止因子の酵素活性阻害剤 |
| US10004828B2 (en) | 2005-10-11 | 2018-06-26 | Romat at Tel-Aviv University Ltd. | Self-assembled Fmoc-ff hydrogels |
| GB2463833B (en) * | 2007-06-26 | 2012-02-08 | Parkinson S Inst | Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders |
| JP5738755B2 (ja) * | 2008-05-09 | 2015-06-24 | アイカーン スクール オブ メディシン アット マウント シナイ | 神経変性疾患を予防および治療するための方法 |
| JP6068484B2 (ja) | 2011-10-24 | 2017-01-25 | ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． | トランスサイレチン関連アミロイドーシスの新規療法 |
| US20180271927A1 (en) * | 2015-05-27 | 2018-09-27 | Nippon Paper Industries Co., Ltd. | Brain function-protecting agent |
| KR102441381B1 (ko) * | 2016-07-18 | 2022-09-07 | (주)아모레퍼시픽 | 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물 |
| JPWO2019054461A1 (ja) * | 2017-09-15 | 2020-08-27 | 株式会社明治 | 神経機能の維持または回復用組成物 |
| CN109799352B (zh) * | 2019-01-29 | 2022-03-08 | 北京健坤禾润科技有限公司 | 化学发光试剂及其在免疫检测中应用 |
| JP2025513275A (ja) * | 2022-04-20 | 2025-04-24 | サンテック メディカル，インコーポレイティド | 中枢神経系疾患の治療方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1275905B1 (it) * | 1995-03-14 | 1997-10-24 | Indena Spa | Frazioni polifenoliche di te', loro uso e formulazioni che le contengono |
| JPH10245342A (ja) * | 1997-03-03 | 1998-09-14 | Mitsui Norin Kk | β−アミロイド蛋白の神経細胞毒性低減剤 |
| WO1998051302A1 (en) * | 1997-05-15 | 1998-11-19 | University Of Washington | Composition and methods for treating alzheimer's disease and other amyloidoses |
| US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| EP1246632A4 (en) * | 1999-12-30 | 2004-08-18 | Proteotech Inc | CATECHINE AND GREEN TEA EXTRACT FOR TREATING AMYLOIDOSES IN GENERAL OR. AT ALZHEIMER |
-
2002
- 2002-03-15 PT PT02721413T patent/PT1372682E/pt unknown
- 2002-03-15 WO PCT/US2002/007755 patent/WO2003013442A2/en not_active Ceased
- 2002-03-15 AT AT02721413T patent/ATE555807T1/de active
- 2002-03-15 ES ES02721413T patent/ES2387910T3/es not_active Expired - Lifetime
- 2002-03-15 EP EP02721413A patent/EP1372682B1/en not_active Expired - Lifetime
- 2002-03-15 CA CA2440293A patent/CA2440293C/en not_active Expired - Fee Related
- 2002-03-15 JP JP2003518456A patent/JP2004537576A/ja active Pending
- 2002-03-15 NZ NZ528321A patent/NZ528321A/en not_active IP Right Cessation
- 2002-03-15 DK DK02721413.9T patent/DK1372682T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2440293A1 (en) | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders | |
| FI86299B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara -alkyl-4-amino-3-kinolinmetanoler. | |
| JP2008520589A5 (enExample) | ||
| US20130059900A1 (en) | Crystal form i of (s)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, preparing method and use thereof | |
| PT1029853E (pt) | Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos | |
| EA200970670A1 (ru) | Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс | |
| YU37203A (sh) | Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonisti | |
| NZ591504A (en) | 3,5-bis(3,4dihydroxyphenyl)pyrazole, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies | |
| WO2004032845A2 (en) | R-nsaid esters and their use | |
| WO2009136408A1 (en) | Synergistic pharmaceutical cocrystals | |
| JP2005505497A5 (enExample) | ||
| CN101001670B (zh) | 用于睡眠障碍的组合物 | |
| WO2005000863A3 (en) | 6, 11-4c-bicyclic 9a-azalide derivatives | |
| US20220064123A1 (en) | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | |
| CA2441099A1 (en) | Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases | |
| NZ239437A (en) | Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalanes to treat dementia and cerebrovasular disorders and for inhibiting platelet aggregation | |
| JP2024149650A (ja) | アルドケトレダクターゼ阻害剤およびその使用 | |
| JP2025523655A (ja) | テトラサイクリン誘導体 | |
| US8496975B2 (en) | Compositions for the treatment and prevention of infections of the oral cavity | |
| WO2004105779A2 (en) | Green tea and oplyphenol inhibitors of bacterial proteases | |
| US8148421B2 (en) | Phenylacetic acid derivative | |
| US9744189B1 (en) | Compositions of lithium salts and methods of use | |
| CA2606427A1 (en) | Green tea polyphenol alpha secretase enhancers and methods of use | |
| AU2002362008A1 (en) | Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease | |
| WO2008080268A8 (zh) | 取代的酒石酸衍生物及其用于制备 |